Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.70 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.70 |
| ▸ | ITGAL | P20701 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12749847 | 0.94 | ITGB2 (0.64) | ITGB2ICAM1ITGAL | |
| SCHEMBL879362 | 0.94 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL13302883 | 0.88 | ITGB2 (0.69) | ITGB2ICAM1ITGAL | |
| SCHEMBL23386105 | 0.86 | ITGB2 (0.67) | ITGB2ICAM1ITGAL | |
| SCHEMBL13821874 | 0.82 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL13813636 | 0.81 | ITGB2 (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL13813632 | 0.81 | ITGB2 (0.79) | ITGB2ICAM1ITGAL | |
| SCHEMBL17991451 | 0.77 | ITGB2 (0.70) | ITGB2ICAM1ITGAL | |
| SCHEMBL10129831 | 0.76 | ITGB2 (0.81) | ITGB2ICAM1ITGAL | |
| SCHEMBL18362420 | 0.75 | ITGB2 (0.67) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071617-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124669-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20120035154-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.